CN110669034B - Isoflavone-chalcone dimer and chalcone dimer, preparation method and application - Google Patents
Isoflavone-chalcone dimer and chalcone dimer, preparation method and application Download PDFInfo
- Publication number
- CN110669034B CN110669034B CN201910940174.9A CN201910940174A CN110669034B CN 110669034 B CN110669034 B CN 110669034B CN 201910940174 A CN201910940174 A CN 201910940174A CN 110669034 B CN110669034 B CN 110669034B
- Authority
- CN
- China
- Prior art keywords
- water
- caragana
- compound
- methanol
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- -1 Isoflavone-chalcone dimer Chemical class 0.000 title abstract description 5
- 150000001788 chalcone derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 241001061906 Caragana Species 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 15
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 7
- 238000000605 extraction Methods 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 96
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 238000010828 elution Methods 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- 241000220485 Fabaceae Species 0.000 claims description 5
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 238000002953 preparative HPLC Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 240000005020 Acaciella glauca Species 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 235000003499 redwood Nutrition 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 7
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 6
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 6
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 230000000302 ischemic effect Effects 0.000 abstract description 5
- 150000001789 chalcones Chemical class 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 2
- 239000000539 dimer Substances 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- 229930003944 flavone Natural products 0.000 abstract description 2
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 2
- 235000011949 flavones Nutrition 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000009897 systematic effect Effects 0.000 abstract description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
- 238000001228 spectrum Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 229940100601 interleukin-6 Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 229940125904 compound 1 Drugs 0.000 description 9
- 229940126214 compound 3 Drugs 0.000 description 9
- 229940125782 compound 2 Drugs 0.000 description 8
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000005100 correlation spectroscopy Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 5
- 241000792739 Caragana changduensis Species 0.000 description 4
- 241000223025 Caragana microphylla Species 0.000 description 4
- 238000003775 Density Functional Theory Methods 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 4
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000785897 Caragana jubata Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229930190697 caraganin Natural products 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002212 electronic circular dichroism spectrum Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an isoflavone-chalcone dimer and a chalcone dimer, a preparation method and application thereof, wherein four novel flavone dimer compounds provided by the invention have the activity of inhibiting IL-6, TNF-alpha and NO generation by carrying out extraction and separation on Tibetan medicine caragana and systematic chemical component research and inflammation medium inhibition activity evaluation, and can be used for preparing medicaments for resisting inflammation and treating ischemic cardiovascular and cerebrovascular diseases.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to isoflavone-chalcone dimers (caraganins A and B) and chalcone dimers (caraganins C and D) in Tibetan medicine caragana, and a preparation method and application thereof.
Background
Caragana tibetana is taken as one of the main Tibetan medicines for blood breaking and stasis removal in Tibetan medicine, and is mainly prepared by using red wood hearts of three plants, namely Caragana microphylla (Caragana jubata), caragana changduensis (Caragana changduensis) and Caragana chuanensis (Caragana tibetaca) in Caragana of Leguminosae of Qinghai-Tibet and high-altitude. The caragana tibetana has the main effects of breaking blood, dissolving stasis and reducing blood pressure, and is commonly used for treating diseases such as hyperemia, hypertension, irregular menstruation and the like.
Inflammation is a process by which human tissues produce a self-protective response when a foreign pathogen and harmful stimuli invade the human body, involving the local vascular system and the immune system, as well as a variety of molecular mediators in damaged tissues. However, uncontrolled inflammation may lead to a range of diseases. Ischemic cardiovascular and cerebrovascular diseases are one of the most serious diseases in human beings, and can cause pathological changes in the body, which are caused by such uncontrolled inflammation. Therefore, controlling the cascade activation of inflammatory mediators such as interleukin-6 (IL-6), tumor necrosis factor (TNF- α) and Nitric Oxide (NO) is a promising approach for the treatment of inflammatory diseases as well as ischemic cardiovascular and cerebrovascular diseases.
Disclosure of Invention
The invention provides an isoflavone-chalcone dimer and a chalcone dimer, a preparation method and application thereof, and solves the problem that few medicines for treating inflammatory diseases can be selected in the prior art.
The technical scheme of the invention is as follows:
a compound represented by the following structure:
the preparation method of the compound comprises the following steps:
(1) Pulverizing radix Caraganae Sinicae, extracting with solvent, and recovering extractive solution to obtain total extract;
(2) Dispersing the total extract obtained in the step (1) in water, extracting by adopting an organic solvent which is immiscible with water, and recovering the solvent to obtain an extract;
(3) Separating the extract obtained in the step (2) by medium-pressure liquid chromatography, and performing gradient elution by using a methanol/water or acetonitrile/water mixed solvent as a mobile phase;
(4) Separating the fractions obtained in the step (3) by preparative high performance liquid chromatography, and performing gradient elution by using methanol/water or acetonitrile/water as a mobile phase to obtain the compounds 1-4.
The Caragana tibetana is red wood heart of rhizome of Caragana microphylla (Caragana jubata) of Caragana of Leguminosae (Leguminosae), caragana changduensis (Caragana changduensis) and Caragana chuanensis (Caragana tibetaca).
The extraction method in the step (1) is heating reflux extraction, leaching, percolation or ultrasonic extraction, the used solvent is at least one of dichloromethane, chloroform, ethyl acetate, methanol, ethanol and methanol-water or ethanol-water with the concentration of more than 60%, and the weight-volume ratio of the medicinal materials to the solvent is 1: 4-1: 15.
In the extraction method in the step (2), the organic solvent is any one of dichloromethane, chloroform, diethyl ether and ethyl acetate, and the volume ratio of the aqueous solution to the organic solvent is 1: 1-1: 2.
In the step (3), gradient elution is carried out by a methanol/water system of 25: 75-100: 0, or gradient elution is carried out by an acetonitrile/water system of 20: 80-90: 10. Wherein the optimized ratio of the methanol/water system is 40: 60-95: 5, and the optimized ratio of the acetonitrile/water system is 35: 65-80: 20.
In the step (4), methanol/water or acetonitrile/water is subjected to gradient elution in a volume ratio of 30: 70-90: 10, and the optimal ratio is 50: 50-80: 10.
A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
The compound and the pharmaceutical composition are applied to the preparation of anti-inflammatory and ischemic cardiovascular and cerebrovascular disease drugs.
The anti-inflammatory agent is an agent that inhibits the activity of IL-6, TNF-alpha, and NO production.
The invention has the beneficial effects that: through systematic chemical component research and inflammation medium inhibition activity evaluation on the Tibetan medicine Caragana tibetana, research finds that the four novel flavone dimer compounds provided by the invention have the activity of inhibiting the generation of IL-6, TNF-alpha and NO, and can be used for preparing medicaments for resisting inflammation and treating ischemic cardiovascular and cerebrovascular diseases.
Drawings
FIG. 1 HRESIMS spectra of Compound 1 of the invention;
FIG. 2 preparation of Compound 1 of the present invention 1 H-NMR spectrum;
FIG. 3 preparation of Compound 1 of the present invention 13 C-NMR spectrum;
FIG. 4 DEPT-135 spectrum of Compound 1 of the present invention;
FIG. 5 preparation of Compound 1 of the present invention 1 H, 1 H COSY spectra;
FIG. 6 HSQC spectra of Compound 1 of the present invention;
FIG. 7 HMBC spectra of Compound 1 of the present invention;
FIG. 8 HRESIMS spectra of Compound 2 of the invention;
FIG. 9 preparation of Compound 2 of the present invention 1 H-NMR spectrum;
FIG. 10 preparation of Compound 2 of the present invention 13 C-NMR spectrum;
FIG. 11 DEPT-135 spectrum of Compound 2 of the present invention;
FIG. 12 preparation of Compound 2 of the present invention 1 H, 1 H COSY spectrum;
FIG. 13 HSQC spectra of Compound 2 of the present invention;
FIG. 14 HMBC spectra of Compound 2 of the present invention;
FIG. 15 HRESIMS spectra of Compound 3 of the invention;
FIG. 16 preparation of Compound 3 of the present invention 1 H-NMR spectrum;
FIG. 17 preparation of Compound 3 of the present invention 13 C-NMR spectrum;
FIG. 18 DEPT-135 spectrum of Compound 3 of the present invention;
FIG. 19 preparation of Compound 3 of the present invention 1 H, 1 H COSY spectrum;
FIG. 20 HSQC spectra of Compound 3 of the present invention;
FIG. 21 HMBC spectra of compound 3 of the invention;
FIG. 22 NOESY spectrum of Compound 3 of the present invention;
FIG. 23 HRESIMS spectra of Compound 4 of the invention;
FIG. 24 preparation of Compound 4 of the present invention 1 H-NMR spectrum;
FIG. 25 of Compound 4 of the present invention 13 C-NMR spectrum;
FIG. 26 DEPT-135 spectrum of Compound 4 of the present invention;
FIG. 27 of Compound 4 of the present invention 1 H, 1 H COSY spectrum;
FIG. 28 HSQC spectra of Compound 4 of the present invention;
FIG. 29 HMBC spectrum of compound 4 of the present invention;
FIG. 30 NOESY spectrum of Compound 4 of the present invention;
FIG. 31 HMBC and of compounds 1-4 of the present invention 1 H- 1 H COSY correlation diagram;
FIG. 32 NOESY-related schematic diagrams of compounds 3 to 4 of the present invention;
FIG. 33 Experimental and calculated ECD spectra of compounds 1-4 of the present invention;
FIG. 34 structural formulas of compounds 1 to 4 of the present invention.
Detailed Description
The present invention is further illustrated below with reference to specific examples, which are intended to be illustrative only and not to limit the scope of the invention.
Example 1
(1) 1 kg of Tibetan caragana medicinal material (original plant caragana microphylla), crushing, extracting for 3 times by using 95% ethanol at room temperature, soaking for 24 hours by 5L each time, and recovering the solvent under reduced pressure to obtain a 95% ethanol extract;
(2) Dispersing the 95% ethanol extract obtained in the step (1) in water to prepare a suspension, extracting with petroleum ether to remove impurities, then extracting with dichloromethane, and recovering the solvent to obtain a dichloromethane extract;
(3) Separating the extract obtained in the step (2) by medium-pressure liquid chromatography (reverse phase silica gel C18), and performing gradient elution by using a methanol/water mixed solvent as a mobile phase (35;
(4) The methanol/water (45: 55 to 65: 35) fractions obtained in the above step (3) were separated by preparative high performance liquid chromatography (reverse phase silica gel C18), and gradient elution was carried out with acetonitrile/water as a mobile phase (45: 55 to 60) to obtain new compound 1 (yield 0.0012%), 2 (yield 0.001%), 3 (yield 0.0008%), and 4 (yield 0.0005%).
Example 2
(1) 2 kg of Tibetan caragana (original plant, changdu caragana), crushing, soaking in 85% ethanol at room temperature for 8 hours, then refluxing and extracting for 3 times, wherein the refluxing is carried out for 8L multiplied by 1 hour each time, and recovering the solvent under reduced pressure to obtain 85% ethanol extract;
(2) Dispersing the 85% ethanol extract obtained in the step (1) in water to prepare a suspension, extracting with petroleum ether to remove impurities, extracting with ethyl acetate, and recovering the solvent to obtain an ethyl acetate extract;
(3) Separating the extract obtained in the step (2) by medium-pressure liquid chromatography (reverse phase silica gel C18), and performing gradient elution (25: 75-80: 20) by using an acetonitrile/water mixed solvent as a mobile phase;
(4) The methanol/water (40: 60 to 60: 40) fractions obtained in the above step (3) were separated by preparative high performance liquid chromatography (reverse phase silica gel C18), and gradient elution (50: 50 to 90: 10) was carried out using acetonitrile/water as a mobile phase to obtain the novel compounds 1 (yield 0.0015%), 2 (yield 0.0011%), 3 (yield 0.0009%), and 4 (yield 0.0008%).
Example 3
(1) 1 kg of Tibetan caragana (original plant caragana microphylla), crushing, soaking in 75% ethanol for 4 hours at room temperature, extracting for 3 times by ultrasonic oscillation (ultrasonic frequency: 40KHz, ultrasonic power: 500W) for 4.5L multiplied by 1 hour each time, and recovering the solvent under reduced pressure to obtain 75% ethanol extract;
(2) Dispersing the 75% ethanol extract obtained in the step (1) in water to prepare a suspension, extracting with petroleum ether to remove impurities, extracting with chloroform, and recovering the solvent to obtain a chloroform extract;
(3) Separating the extract obtained in the step (2) by medium-pressure liquid chromatography (reverse phase silica gel C18), and performing gradient elution (40: 60-95: 5) by using a methanol/water mixed solvent as a mobile phase;
(4) The methanol/water (47: 53 to 68: 32) fractions obtained in the above step (3) were separated by preparative high performance liquid chromatography (reverse phase silica gel C18), and gradient elution (30: 70 to 65: 35) was carried out using acetonitrile/water as a mobile phase to obtain novel compounds 1 (yield 0.0010%), 2 (yield 0.0009%), 3 (yield 0.0010%), and 4 (yield 0.0003%).
Experimental example 1
The structures of the compounds 1 to 4 were identified based on their physicochemical properties and spectral data (see FIGS. 1 to 34 for the spectral analysis of the compounds 1 to 4). The structural identification data for compound 1 is as follows:
yellow powder (MeOH); [ alpha ] to] 22 D -1.2(c 0.09,MeOH)；UV(MeOH)λ max (logε)261(4.38)nm；ECD(MeOH)λ max (Δε)206(+10.49),220(+5.06),240(-7.00)nm；IR(KBr)ν max 3439,2921,1653,1610,1567,1549,1513,1464,1450,1438,1309,1265,1208,1112,1030,667,660cm -1 ； 1 H NMR(DMSO-d 6 600 MHz) and 13 C NMR(DMSO-d 6 150 MHz) data are shown in Table 1; HRESIMS m/z 591.1614[ m + Na ])] + ,calcd for C 33 H 28 NaO 9 ,591.1626. The HMBC related signals of the compounds are shown in FIG. 31 (1). The absolute configuration of the compound is determined by an ECD map determined by a comparative experiment and an ECD map of an enantiomer obtained by calculation by adopting a TDDFT (time density functional theory) method. The absolute configuration of the compound was determined to be 9' R, ECD map as shown in FIG. 33 (A).
The structural identification data for compound 2 is as follows:
yellow powder (MeOH); [ alpha ] of] 22 D -1.0(c 0.09,MeOH)；UV(MeOH)λ max (logε)261(4.26)nm；ECD(MeOH)λ max (Δε)227(-26.82),239(-14.46),254(+6.41),284(+10.21)nm；IR(KBr)ν max 3433,2922,1612,1508,1459,1263,1207,1158,1039,559cm -1 ； 1 H NMR(DMSO-d 6 400 MHz) and 13 C NMR(DMSO-d 6 100 MHz) data are shown in Table 1; HRESIMS m/z 567.1666[ M-H ]] - ,calcd for C 33 H 27 O 9 ,567.1661. The HMBC related signals of the compounds are shown in FIG. 31 (2). The absolute configuration of the compound is determined by comparing an ECD map determined by an experiment and an ECD map of an enantiomer obtained by calculation by adopting a TDDFT (time density functional theory) method. The absolute configuration of the compound was determined to be 9' R, ECD map as shown in FIG. 33 (B).
The structural identification data for compound 3 is as follows:
light yellow oil (MeOH); [ alpha ] to] 22 D -1.0(c 0.08,MeOH)；UV(MeOH)λ max (logε)274(3.99)nm；ECD(MeOH)λ max (Δε)214(+3.59),221(+10.00),239(-12.70)nm；IR(KBr)ν max 3432,2928,2378,1617,1508,1453,1378,1265,1208,1157,1119,1037,929,832cm -1 ； 1 H NMR(DMSO-d 6 600 MHz) and 13 C NMR(DMSO-d 6 150 MHz) data are shown in Table 2; HRESIMS m/z 547.2072[ M + [ Na ]] + ,calcd for C 33 H 32 NaO 6 ,547.2091. The HMBC related signals of the compounds are shown in FIG. 31 (3), and the NOESY related signals are shown in FIG. 32 (3). The absolute configuration of the compound is determined by an ECD map determined by a comparative experiment and an ECD map of an enantiomer obtained by calculation by adopting a TDDFT (time density functional theory) method. The absolute configuration of the compound is determined as 2R,3R,4R, ECD map as shown in FIG. 33 (C).
The structural identification data for compound 4 is as follows:
light yellow powder (MeOH); [ alpha ] to] 22 D +1.2(c 0.10,MeOH)；UV(MeOH)λ max (logε)267(3.79)nm；ECD(MeOH)λ max (Δε)219(-4.50),231(+24.10),243(-20.00),267(+16.65),290(+10.85)nm；IR(KBr)ν max 3438,2923,2853,1616,1513,1443,1261,1159,1024,804,578cm -1 ； 1 H NMR(DMSO-d 6 600 MHz) and 13 C NMR(DMSO-d 6 150 MHz) data are shown in Table 2; HRESIMS m/z 507.1811[ M-H ]] - ,calcd for C 32 H 27 O 6 ,507.1813. The HMBC and NOESY-related signals of the compounds are shown in FIG. 31 (4) and FIG. 32 (4). The absolute configuration of the compound is determined by an ECD map determined by a comparative experiment and an ECD map of an enantiomer obtained by calculation by adopting a TDDFT (time density functional theory) method. The absolute configuration of the compound is determined as 2S,3R,4R, ECD map as shown in FIG. 33 (D).
TABLE 1 of Compounds 1 and 2 1 H and 13 c NMR data (DMSO-d) 6 )
TABLE 2 of Compounds 3 and 4 1 H and 13 c NMR data (DMSO-d) 6 )
Experimental example 2
Anti-inflammatory Activity test of novel Compounds 1 to 4
Lipopolysaccharide (LPS) is adopted to induce macrophage of a RAW264.7 mouse to generate a model of NO, IL-6 and TNF-alpha, and the anti-inflammatory activity of the model is evaluated by detecting the expression levels of three inflammatory mediators in RAW264.7 cells after a test compound is added, so that potential drugs for resisting inflammation and treating ischemic cardiovascular and cerebrovascular diseases are discovered.
1. Method for preparing test compound solution
Test compounds were dissolved in DMSO to prepare a stock solution at a concentration of 50mM and stored at-20 ℃. The test was carried out by diluting the medium with DMEM in the order of 10mM, 5mM, 3mM, 1mM, 0.1mM, and 0.01mM.
2. Culture of mouse RAW264.7 macrophage
Preparing a culture medium containing 10% fetal bovine serum and 1% diabody (penicillin: streptomycin = 1: 1) cells based on DMEM medium, at 37 deg.C, 5% CO 2 Culturing in an incubator, and changing the culture solution once in 2-3 days until the cells are fully paved on the bottom of the culture bottle for testing.
3. Cytotoxicity of test Compounds
Adjusting the cell density of the cells in logarithmic growth phase to 1 × 10 5 seed/mL, in 96-well plates, at 37 ℃,5% CO 2 After 24 hours of incubation in an incubator, different concentrations of test compound were added, and after 20 hours, cell survival was observed and MT was usedThe T-method quantifies the toxicity of a compound to a cell to determine the test concentration of the test compound.
Detection of NO inhibitory Activity
RAW264.7 cells in the logarithmic growth phase were seeded in 96-well plates (1X 10) at an adjusted cell density 4 One/well), culturing for 24 hours, adding the compounds to be treated with different concentrations after the cells are completely attached to the wall, pretreating for 30min, adding LPS until the final concentration is 1.0 mu g/mL, and continuously culturing for 24 hours. And (3) taking 160 mu L of cell culture supernatant, adding 80 mu L of Griess reagent, measuring absorbance at the wavelength of 550nm according to a Griess method, and calculating the inhibition rate of each compound to NO according to the absorbance value and a standard curve.
Detection of IL-6 and TNF-alpha inhibitory Activity
RAW264.7 cells in logarithmic growth phase were seeded in 96-well plates (1X 10) 5 One/hole), culturing for 24 hours, adding the compounds to be treated with different concentrations after the cells are completely attached to the wall, pretreating for 30min, adding LPS until the final concentration is 10ng/mL, and continuously culturing for 24 hours. The extracted RNA was reverse transcribed into cDNA using ELISA kits for IL-6 and TNF-. Alpha.determination, and mRNA expression level measurements of IL-6 and TNF-. Alpha.were performed using a real-time quantitative PCR method to determine the inhibitory effect of each compound on the inflammatory response induced by LPS.
6. Statistical method
All data were processed and analyzed using the SPSS (V17.0) statistical software package. Results are expressed as standard error of the mean. Calculating IC of each compound by nonlinear regression fitting of parameters such as each dose and inhibition rate 50 The value is obtained.
TABLE 3 IC inhibition of NO production and IL-6, TNF-alpha secretion by novel Compounds 1-4 50 Value (μ M)
a Dexamethasone (dexamethasone) was used as a positive control drug.
The data in Table 3 show that the new compounds 1-4 can obviously inhibit the generation of NO and/or the expression level of IL-6, TNF-alpha mRNA in mouse macrophage RAW264.7 induced by Lipopolysaccharide (LSP) and show dose dependence, and the compounds have obvious anti-inflammatory activity and can be used for preparing new anti-inflammatory activity medicaments.
The invention is not limited to the embodiments described above, many variations in detail are possible without departing from the scope and spirit of the invention.
Claims (9)
1. A compound represented by the following structure:
2. a process for the preparation of a compound according to claim 1, comprising the steps of:
(1) Pulverizing radix Caraganae Sinicae, extracting with solvent, and recovering extractive solution to obtain total extract;
(2) Dispersing the total extract obtained in the step (1) in water, extracting by adopting an organic solvent immiscible with water, and recovering the solvent to obtain an extract;
(3) Separating the extract obtained in the step (2) by medium-pressure liquid chromatography, and performing gradient elution by using a methanol/water or acetonitrile/water mixed solvent as a mobile phase;
(4) Separating the fractions obtained in the step (3) by preparative high performance liquid chromatography, and performing gradient elution by using methanol/water or acetonitrile/water as a mobile phase to obtain compounds 1-4;
the extraction method in the step (1) is heating reflux extraction, leaching, percolation or ultrasonic extraction, the used solvent is at least one of methanol, ethanol and methanol-water or ethanol-water with the concentration of more than 60%, and the weight-volume ratio of the medicinal materials to the solvent is 1: 4-1: 15;
in the extraction method in the step (2), the organic solvent is any one of dichloromethane, chloroform and ethyl acetate, and the volume ratio of the aqueous solution to the organic solvent is 1: 1-1: 2.
3. The method of producing the compound according to claim 2, wherein the Caragana tibetana is a red wood heartwood of a rhizome of Caragana guichenensis (Caragana jubatata), caragana changdunensis (Caragana changdiensis) and Caragana chuanensis (Caragana tibetaca) belonging to genus Caragana of family Leguminosae (Leguminosae).
4. The method for preparing the compound according to claim 2, wherein the elution is carried out in a gradient of 25: 75 to 100:0 in a methanol/water system or in a gradient of 20: 80 to 90: 10 in an acetonitrile/water system in the step (3).
5. The method for preparing the compound according to claim 2, wherein the methanol/water or acetonitrile/water in the step (4) is eluted at a gradient of 30: 70 to 90: 10 by volume ratio.
6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
7. Use of a compound according to claim 1 for the manufacture of an anti-inflammatory medicament.
8. Use of a pharmaceutical composition according to claim 6 for the preparation of an anti-inflammatory medicament.
9. The use according to claim 8, wherein the anti-inflammatory agent is an agent having an activity of inhibiting the production of IL-6, TNF-a and NO.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910940174.9A CN110669034B (en) | 2019-09-30 | 2019-09-30 | Isoflavone-chalcone dimer and chalcone dimer, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910940174.9A CN110669034B (en) | 2019-09-30 | 2019-09-30 | Isoflavone-chalcone dimer and chalcone dimer, preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110669034A CN110669034A (en) | 2020-01-10 |
| CN110669034B true CN110669034B (en) | 2022-11-25 |
Family
ID=69080406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910940174.9A Expired - Fee Related CN110669034B (en) | 2019-09-30 | 2019-09-30 | Isoflavone-chalcone dimer and chalcone dimer, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110669034B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112625048A (en) * | 2020-12-16 | 2021-04-09 | 顺德职业技术学院 | Novel flavane compound of dianella root and preparation method thereof |
| CN114085257B (en) * | 2021-07-30 | 2023-10-31 | 天津大学 | Para-benzofurancaprolactam and two phenylpropanoid glycosides, preparation and use thereof |
| CN116283873A (en) * | 2023-03-21 | 2023-06-23 | 扬州大学 | Preparation method of kyunonin and application of kyunonin in resisting ischemic cerebral apoplexy and Alzheimer's disease |
-
2019
- 2019-09-30 CN CN201910940174.9A patent/CN110669034B/en not_active Expired - Fee Related
Non-Patent Citations (5)
| Title |
|---|
| Antiplasmodial dimeric chalcone derivatives from the roots of Uvaria siamensis;Abdul-Wahab Salae et al.;《Phytochemistry》;20171231;第135-143页 * |
| Isoflavones and pterocarpans from Caragana changduensis;Xiaodong Sun et al.;《Biochemical Systematics and Ecology》;20151231;第516-519页 * |
| Isoflavonoids and norneolignan from Caragana changduensis;Lina Guo et al.;《Phytochemistry Letters》;20171231;第32-35页 * |
| 昌都锦鸡儿异黄酮类成分及其抑制NO生成活性;孙晓东等;《中国中药杂志》;20150815(第16期);第3220-3223页 * |
| 鬼箭锦鸡儿细胞毒活性成分研究;杨新洲等;《云南大学学报(自然科学版)》;20150110(第01期);第134-139页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110669034A (en) | 2020-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110669034B (en) | Isoflavone-chalcone dimer and chalcone dimer, preparation method and application | |
| AU2022352631B2 (en) | Azulene compound, and preparation method therefor and use thereof | |
| CN103804443A (en) | Flavonoid glycoside compound and preparation method thereof | |
| Kim et al. | Chemical constituents of the rhizome of Eleutherine bulbosa and their inhibitory effect on the pro-inflammatory cytokines production in lipopolysaccharide-stimulated bone marrow-derived dendritic cells | |
| CN112898357B (en) | Diterpene glycoside novel compound in trollius chinensis bunge and separation and purification method and application thereof | |
| CN103494806B (en) | Application of benzene a pair of horses going side by side alpha-pyrone compound and preparation method thereof | |
| CN112079804A (en) | Lactuca indica bitter and application thereof as anti-inflammatory component | |
| CN104382968A (en) | Method for extracting common andrographis paniculata total lactone, pharmaceutical composition of andrographis paniculata total lactone and use of pharmaceutical composition | |
| CN108017600A (en) | Six kinds from terpenoid of Common Sage Herb and its preparation method and application | |
| CN103739652A (en) | New 23, 29-drop oleanolic acid compound, preparation method thereof and application in preparation of glucosidase inhibitor medicines | |
| CN108948038B (en) | Neopteridine flavonoid compound and application thereof | |
| CN115991692A (en) | Preparation method and application of spirodienone lignan compound in Isatis tinctoria | |
| CN111454153B (en) | Five ent-tisane diterpene compounds from euphorbia humifusa and preparation method and application thereof | |
| CN114644608A (en) | Fisetin with urate transporter 1 inhibitory activity and preparation method and application thereof | |
| CN114085257B (en) | Para-benzofurancaprolactam and two phenylpropanoid glycosides, preparation and use thereof | |
| CN105646638B (en) | The preparation method of pedunculoside | |
| CN112939912A (en) | Preparation method and application of lactucin extracted from cichorium intybus | |
| CN113248483A (en) | Preparation method and application of lawn pennywort herb flavone glycoside monomer isovitexin | |
| CN111777512A (en) | Five diterpenoid compounds derived from euphorbia tirucalli as well as preparation method and application thereof | |
| CN115558011B (en) | Anthracene ketone compound and preparation method and application thereof | |
| CN110354116A (en) | A kind of preparation method and application of saussurea intybus lignin extract | |
| CN103641882A (en) | Novel 2,3-dihydroxyl-30-noroleanolic acid as well as preparation method and application thereof in preparing glycosidase inhibitor medicament | |
| CN117462541B (en) | Application and extraction method of des-O-methyl lasiodiplodin | |
| RU2783445C1 (en) | Method for isolation and purification of baicalin from root cultures of scutellaria baicalensis georgi | |
| CN107840822B (en) | Euphorbia lathyris alcohol and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20221125 |